Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
0.50 or higher by close
3.6 million shares traded in 15 minutes since the bell. Go NWBO!!! It's time!!!!
I agree, these "exit" strategies will be purely independent, individualized, and subjective. In my case, I have had every penny to my name invested into 100,800 shares of this company since 2017. My average pps is 0.23.
I am about $300k in debt including school loans and mortgage. At the least, my plan is to get the slate clean and be debt free, so I need the pps to reach a certain milestone. Ideally, if TLD is positive and pps really starts climbing, my plan is to sell off only what I need to cover my debt and let the remaining shares keep riding. On the other hand, if it's a home run, I may just hold on for dear life and completely cash out when I feel comfortable or of course take what I get from a buyout.
I am personally hoping for buyout or partnership.
But yes, everyone has different strategies and motives regarding their investments in the company, and will exit accordingly based on their own motives and agendas. I'm in a "do or die" mentality with my investment. This will either make or break me. Some would consider that to be purely stupid, others would say I have the biggest balls on the planet. I say... I believe in the science and have taken a calculated risk. I've shoveled shi* my entire life regarding career and finances, I come from poverty on both sides of my family, and really have nothing to lose. I've served my country, I'm educated and will soon be a nurse practitioner, I've adopted two children....I've tried to do right and set myself up for success but school loans and setbacks have kept me from being able to realize my "American Dream". I'm risking it all (which isn't much) to secure my financial future via investment in a high risk penny stock with an immunotherapy company on the verge of something that I believe is a game changer.
GLTA!
It is immunotherapies version of the Henry Ford Assembly line for dcvax. Probably a bad analogy but it speeds up automation
NWBO just acquired Flaskworks
Thanks Marzan!
Compared to side effects of chemo, NWBO is Mother Theresa. ??
So COVID shuts down and delays mostly everything else in this country (even the world) for the better part of the current year and NWBO is not allowed to imply the pandemic is holding things up? Boohoo JR, we're almost at data lock, and I can't wait until TLD is released positive so you will all pi** off!
Could be shareholder pressure via email and phone calls. I dunno
Looking forward to September. GLTA. It's do or die time baby!
Annnnd WRONG. This is the second time I've called out your pseudo-psychic predictions of a red close. Third time's a charm?
Debbie Downer is posting non-stop today. (Waaah wahhhh)
The latest 2020 edition of this report reserves the right to provide further comments on the latest scenarios, recession, and impact of COVID-19 on the entire industry. It also provides qualitative information on when the industry can rethink the goals the industry is taking to address the situation and possible actions.
The report covers extensive analysis of the key market players in the market, along with their business overview, expansion plans, and strategies. The key players studied in the report include:
JW CreaGene
Miltenyi Biotec
GlaxoSmithKline
NorthWest BioTherapeutics
ImmunoCellular Therapeutics
EnoChian Bioscience
Medigene
Tella Incorporation
https://bulletinline.com/2020/08/16/dendritic-cell-and-tumor-cell-cancer-vaccine-market-report-expected-massive-growth-by-2020-2026-jw-creagene-miltenyi-biotec-glaxosmithkline-northwest-biotherapeutics-immunocellular-therapeutics/
Love it!
You can't prove what you are claiming, and I won't hold my breath for you to shut up since you cannot put up. You are just swimming in conjecture, making assumptions about what you THINK is going on behind the scenes with absolutely no proof of anything other than your own perceptions. Add the obviously condescending (I know more and I know better) attitude you bring to the table, and it's just laughable. Seems to be so many psychics as well as those with broad careers and experience bringing clinical trials to market on this board apparently.
Where is the proof? Put up or shut up.
You are full of assumptions and conjecture. That's it. (Yawn)
Why is my TD Ameritrade account only showing 710 million shares outstanding? Can someone school me? Or TD just not updating the outstanding shares? The last 10k also said less than one billion shares outstanding. Why am I seeing people talking about over 1 billion outstanding?
Yes! This! Anyone can read this article.
https://translational-medicine.biomedcentral.com/articles/10.1186/s12967-018-1507-6
If you are pointing to the dcvax-L phase 3 trial, the trial is blinded. Nobody can see the performance results of this treatment until the trial is locked, the data then analyzed by by statisticians, and finally revealed to the public once the results are sent to NWBO and interpreted by an advisory board. None of that has happened yet. So how does anyone know this is a failed trial without publicly admitting on record to criminal activity?
So basically a chubby
TLD date predictions. Go!
Below is the link to the 2005 chloroquine to treat Sars-CoV by NIH. They know it works.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1232869/
Corona is sensationalized by the media and the death numbers are inaccurate. If you can smell a fart through your pants then a cloth mask will not save you. Hydroxychloroquine/Zinc/Azithromycin will save you however.
TODAY WE BREAK 0.40
DCVAX production--->>>
The Corning® MicroDEN system enables the wide use of dendritic cells in cell and gene therapy for basic and applied research in immunology and immune-oncology. Developed by Flaskworks, a Boston-based start-up company specializing in technologies for therapeutic cell production, the Corning MicroDEN system is now available from Corning.
The rise of personalized immunotherapies has increased demand for dendritic cells. However, the current process for generating these cells is cumbersome, error-prone, and time intensive. Dendritic cells are key elements in immunology and immunotherapy research in oncology and infectious diseases as well as autoimmune diseases and transplant rejection. The Corning MicroDEN system streamlines the process by minimizing the manual steps, resulting in more consistent yields, a reduced risk of contamination, and more efficient therapy research.
The Corning MicroDEN system is composed of the MicroDEN unit manufactured by Flaskworks, and closed-system consumables manufactured by Corning, such as tissue culture-treated polystyrene flasks, storage bottles, and tubing. The Corning MicroDEN system is jointly branded with Flaskworks and will be marketed, sold, and supported globally by Corning.
“MicroDEN leverages Corning’s strength in cell culture technology and is a strong strategic fit, addressing key emerging needs in cell therapy research and development,” said Keith Olson, vice president, business operations and technology, Corning Life Sciences. “Using MicroDEN for dendritic cell production provides a streamlined approach differentiated from the current manual processes, saving time for our customers.”
“With the growing applications and importance of dendritic cells in immune-therapy research, it is critical that this system be available to investigators globally. Corning's leadership in cell culture and its global footprint make it an ideal partner for Flaskworks' innovative MicroDEN platform,” said Dr. Shashi Murthy, Flaskworks’ founder and Chief Technology Officer.
0.40+ this week. Final answer, Regis!
Agreed!!
There is an article out there in google-land on why Dendreon failed and what biotechs should take from it's failure for the future. It's like a "how did Rome fall" story with 3 distinct reasons. One of those reasons being overpriced.
Because Dendreon was overpriced and it's efficacy after release was "meh".
Crickets chirping
We can always count on you to be wrong. Thanks for not letting us down. Opened up at 0.26 and closed at 0.34. Like I said before, the only thing that stinks here is your breath.
It came across my TD app via News alerts for NWBO via PR newswire. Just google "PR newswire Northwest Biotherapeutics July 24, 2020."
BETHESDA, Md., July 24, 2020 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB: NWBO) ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today announced that the data collection from all of the clinical trial sites for the Company's Phase 3 trial of DCVax®-L for Glioblastoma brain cancer (the "Trial") has been completed and all of the sites have signed off on the locking of their data.
As noted in the Company's prior reports, in order to reach overall data lock for the Trial, each site's data must go through final collection, review, checking for queries, resolution of queries preparatory steps for locking the site and finally personal sign-off by the lead investigator at each site for that site's data. For that purpose, the lead investigator must undergo training on the system, review the site data, personally complete the confirmation and deliver it to the independent contract research organization (CRO) managing the Trial.
Reaching these personal sign-offs by each lead investigator at each of the Trial sites has been a key focus of activity towards data lock for the last couple of months, especially during June and July. At the time of the Company's last report near the end of June, about 30 Trial sites were in varying stages of progress towards sign-off, and about half a dozen Trial sites had not yet completed the preparatory steps necessary to begin the process towards such sign-off.
All of the Trial sites are now finished. The independent CRO has obtained all of the investigator sign-offs for their site's data lock. The sites' data includes all of the clinical data gathered in the Case Report Forms throughout the Trial, and now sit in a signed off, locked position with the CRO.
These datasets from each of the Trial sites (hospitals) are the largest component of the overall dataset for the Trial and contain most of the data. The remaining information for the overall Trial dataset includes some analyses from specialized service providers who are separate from the Trial site hospitals. Such analyses include, for example, genetic profiles such as IDH mutations. For some of these analyses, it has been necessary to go back and obtain additional material due to the age of the samples. For other analyses, it has been necessary to have the analyses done by two separate experts as a cross-check.
This process continues to be impacted by the effects of COVID-19, especially with the resurgence of COVID cases in many areas. For example, key experts at certain specialized service providers have been unavailable for periods of time due to illness in their family. Other experts have gone on extended leave due to restrictions on operations. However, the CRO and the Company are working intensively with these vendors on a continuous basis to move as quickly as possible.
The Company currently anticipates that the remaining analyses by these specialty service providers will be completed within the next couple weeks. When this external data joins the now locked data from the Trial sites, the overall Trial dataset will be locked.
Following completion of the Trial data lock, the independent statisticians will be given access to the raw data in the Trial database, and will undertake the calculations and the preparations of the Tables and Listings which provide the Trial results. The Company anticipates that the statisticians' work will take several weeks.
The Company will remain blinded throughout this period and will not become unblinded until the independent statisticians deliver the initial results to the Company.
When the Company receives the initial results, it will review the data and results with its Scientific Advisory Board, the Trial Steering Committee, and other key advisors. During this process, any questions or comments from the experts will be addressed as part of the preparation of the results for public reporting. The Company anticipates that these very important discussions with experts could take several weeks, especially with the significant logistical challenges due to COVID-related restrictions (which may be further increasing as the COVID resurgence grows).
In light of the significant progress reported here, together with the next steps in the process and the operational and logistical challenges, the Company currently anticipates that Trial results will be ready for reporting approximately sometime after Labor Day in the month of September. The Company will be consulting with its Principal Investigator and experts on the appropriate venue and manner of presenting the Trial results.
The Company will also continue to provide progress reports as key milestones are reached.
Northwest Biotherapeutics is a biotechnology company focused on developing personalized immunotherapy products designed to treat cancers more effectively than current treatments, without toxicities of the kind associated with chemotherapies, and on a cost-effective basis, in both North America and Europe. The Company has a broad platform technology for DCVax® dendritic cell-based vaccines. The Company's lead program is a 331-patient Phase III trial of DCVax®-L for newly diagnosed Glioblastoma multiforme (GBM). GBM is the most aggressive and lethal form of brain cancer, and is an "orphan disease." The Company is also pursuing development of DCVax®-Direct for inoperable solid tumor cancers. It has completed a 40-patient Phase I trial, and is preparing for Phase II trials. The Company previously conducted a Phase I/II trial with DCVax-L for advanced ovarian cancer together with the University of Pennsylvania.
Disclaimer
Statements made in this news release that are not historical facts, including statements concerning future treatment of patients using DCVax and future clinical trials, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "expect," "believe," "intend," "design," "plan," "continue," "may," "will," "anticipate," and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. We cannot guarantee that we actually will achieve the plans, intentions or expectations disclosed in our forward-looking statements and you should not place undue reliance on our forward-looking statements. Actual results may differ materially from those projected in any forward-looking statement. Specifically, there are a number of important factors that could cause actual results to differ materially from those anticipated, such as risks related to the Company's ability to enroll patients in its clinical trials and complete the trials on a timely basis, uncertainties about the clinical trials process, uncertainties about the timely performance of third parties, risks related to whether the Company's products will demonstrate safety and efficacy, risks related to the Company's ongoing ability to raise additional capital, and other risks included in the Company's Securities and Exchange Commission ("SEC") filings. Additional information on the foregoing risk factors and other factors, including Risk Factors, which could affect the Company's results, is included in its SEC filings. Finally, there may be other factors not mentioned above or included in the Company's SEC filings that may cause actual results to differ materially from those projected in any forward-looking statement. The Company assumes no obligation to update any forward-looking statements as a result of new information, future events or developments, except as required by securities laws.
CONTACTS
Dave Innes
Les Goldman
804-513-4758 dinnes@nwbio.com
240-234-0059 lgoldman@nwbio.com
SOURCE Northwest Biotherapeutics
We can only speculate. Nobody really knows.
All hail the bread king!
I really hope so.
3 questions:
1. I wonder what the estimated annual sales of DCVAX-L will be if approved?
2. Will DCVAX-L be cost effective? Even DCVAX direct? Is it going to be priced affordably.
3. This company will surely fail if no buyout with no partnership. Wonder if buyout or partnership will happen and who it will be?
*Look at the failure story of Dendreon and it's drug provenge. I hope NWBO doesn't make the same mistakes if DCVAX products are approved.